Articles tagged with Hiv Treatments
After a stem cell transplant from a donor with the CCR5-delta 32 mutation, a man was able to stop his antiretroviral treatment without viral resurgence. Four years later, no HIV virus could be detected in his body, indicating probable cure. This case joins two previous reported cases and offers further proof that HIV can be cured.
A major clinical trial found that two new simplified HIV treatment options are at least as effective as current approaches in achieving viral suppression. These new regimens offer potential benefits in terms of cost, tolerability, and simplification, making them suitable for low- and middle-income countries.
A study found that long-acting injectable ART suppressed HIV in people with unstable housing, mental illnesses, and substance use disorders. The treatment improved outcomes in underserved patients, overcoming daily treatment barriers such as housing insecurity and untreated mental illnesses.
A 53-year-old man has been cured of HIV after receiving a stem cell transplant, marking the third person to achieve this. The patient's genome contained a mutation in the CCR5 gene, making it impossible for most HIV viruses to enter his CD4+ T-lymphocytes.
The AIDS Clinical Trials Group (ACTG) will present 29 presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023. The studies focus on COVID-19, HIV cure, pathogenesis, treatment, long-term complications, tuberculosis, hepatitis C, and contraception.
A new study reveals that all 50 US states now allow minors to consent independently to some STI/HIV services, but confidentiality protections are rare and vary significantly. The laws remain complex, with gaps in coverage for prevention services like the HPV vaccine and PrEP.
A new study published in The Lancet HIV reveals that women experiencing recent intimate partner violence are three times more likely to contract HIV. The research highlights the intersectional epidemic of IPV and HIV in Sub-Saharan Africa, where women face increased risk of HIV acquisition and less frequent viral load suppression.
A systematic review of national clinical practice guidelines in Europe found that fewer than half include HIV testing recommendations for patients with medical conditions indicating HIV infection. This omission hinders efforts to stop the spread of HIV through timely diagnosis, affecting the lives of people living with HIV.
A study published in The Lancet Ebiomedicine found that HIV patients who used an ingestible sensor system had better antiretroviral therapy adherence and lower viral loads. The research, led by Dr. Eric Daar, showed the technology to be effective in monitoring medication adherence.
Researchers found that people living with HIV have a significantly delayed internal body clock, consistent with the symptoms of jet lag. This disruption may contribute to increased health problems experienced by those with HIV. The study suggests a strong need for further research on younger people living with HIV in other countries.
A new Danish-led study has demonstrated a way to strengthen the body's own ability to fight HIV, even when standard treatment is paused. The study found that monoclonal antibodies and Romidepsin can help the immune system recognize and kill infected cells.
A recent study published in The Lancet HIV found that individuals with viral suppression through antiretroviral therapy (ART) medications can live longer and experience less disability compared to those with unsuppressed HIV. This research highlights the critical importance of maintaining support for HIV treatment programs to ensure op...
Research found that people with HIV who also have untreated hepatitis C virus have a higher risk of heart attack as they age. The study analyzed health data from 23,361 people with HIV and found that those co-infected with hepatitis C had a significantly increased risk of heart attack compared to those with HIV alone.
Researchers discovered 13 cases of asymptomatic MSM with positive monkeypox virus PCR results in anal samples, raising concerns about the outbreak's transmission dynamics. The findings suggest that vaccination may not be an effective strategy for preventing infection, highlighting the need for expanded public health interventions.
A study published in eLife suggests that combining broadly neutralizing antibodies (bNAbs) based on viral genetics can help prevent viral escape and rebound in HIV treatment. The researchers identified a combination of three bNAbs, PG9, PGT151, and VRC01, which reduces the chance of viral rebound to less than 1%.
A new study finds that large-scale HIV screening and peer support successfully reduced uncontrolled HIV in people who inject drugs by 40% in Haiphong, Vietnam. The intervention improved HIV identification and care among this at-risk population.
Researchers at Massachusetts General Hospital found that paclitaxel improves clinical outcomes and is cost-effective compared to commonly used treatments in Kenya. Using paclitaxel instead of bleomycin-vincristine could save 6,400 years-of-life and reduce healthcare expenditures by $3.7 million over five years.
A longitudinal cohort study found significant reductions in liver disease and mortality among people with HCV infection who received treatment. The study's findings suggest that continued testing, treatment, and community-based interventions could lead to the elimination of HCV infection within the next decade.
Researchers aim to develop a gene therapy that could suppress HIV replication and eliminate the need for life-long antiretroviral therapy. The study uses an AAV vector to produce leronlimab, a monoclonal antibody blocking HIV entry into immune cells.
Scientists have determined the molecular structure of HIV Pol, a protein that plays a key role in the late stages of HIV replication. The discovery reveals a new vulnerability in the virus that could be targeted with drugs, and sheds light on how the protein breaks apart to advance the replication process.
Researchers analyzed stored blood samples from infected men and found significant age acceleration in DNA epigenetic measures and telomere shortening. The study demonstrates HIV's substantial impact on the body's aging processes within two to three years of infection.
Researchers aim to understand how HIV affects cardiovascular health and the impact of substance use on this relationship. They plan to develop a human bone marrow chip model to study HIV pathogenesis and explore potential strategies for caring people with HIV who face cardiovascular disease.
A new study from Tel Aviv University developed a unique treatment for AIDS that may be developed into a vaccine or a one time treatment. The treatment involves engineering type B white blood cells to secrete anti-HIV antibodies in response to the virus.
Researchers successfully reprogrammed non-controllers' CD8+ T cells to acquire properties of natural HIV controllers, enabling them to suppress viral load and survive without exhaustion. This breakthrough could lead to a cell therapy strategy for achieving HIV remission, with potential applications in cancer treatments.
New research suggests that ADCC responses and strain susceptibility influence HIV-1 mother-to-child transmission during breastfeeding. Enhancing ADCC through a vaccine may not be sufficient to prevent transmission due to chronically infected individuals' ADCC-resistant strains.
A phase I clinical trial demonstrated the safety and efficacy of a novel adeno-associated viral vector-based treatment for HIV, producing measurable amounts of a broadly neutralizing antibody. The treatment showed wide-ranging clinical implications for potentially preventing or treating HIV and other infections.
PrEP users in Germany experienced infrequent testing, with 26.3% not following recommended frequencies for HIV, STI, and renal function testing. Regular testing is crucial to prevent missed diagnoses and manage asymptomatic STIs, particularly in MSM populations.
Researchers at Northwestern University used CRISPR to identify human genes important for HIV infection in blood cells, finding 86 genes that may play a role in replication and disease. The study proposes a new map for understanding how HIV integrates into the DNA and establishes chronic infections.
Researchers have successfully generated large numbers of virus-resistant immune cells from monkeys using CRISPR/Cas9 gene editing. This breakthrough could lead to the development of a new treatment for HIV/AIDS by providing an alternative to current therapies that require lifelong medication and can cause side effects.
A study in Botswana found that HIV transmission occurs primarily within and between same-age communities, rather than between distant communities. Community-based HIV testing and treatment can effectively curb the spread of the disease if targeted at high-risk populations.
A new study by CUNY SPH researchers estimates that nearly 40% of children living with HIV in sub-Saharan Africa are undiagnosed, highlighting the urgent need for improved pediatric testing coverage. The study found that only 55% of children on ART had suppressed viral loads, underscoring the importance of early diagnosis and treatment.
Researchers at FAU are developing an affordable, disposable self-testing HIV-1 chip that can detect HIV from whole blood samples and measure viral load without refrigeration or skilled technicians. The technology aims to increase access to HIV testing and improve treatment outcomes in any setting.
A global trial led by UCL found that a dolutegravir-based regimen reduced treatment failure among young people aged three to 18 by around 40% compared to standard treatments. The study also showed better growth and lipid profiles in children receiving dolutegravir, making it an effective option for treating HIV in children.
Researchers will test four interventions to determine which combinations are most effective at helping people who inject drugs and who are HIV positive to suppress their viral load. Strategies include patient navigators, psychological therapy, methadone treatment, and educational sessions.
A recent study found that 19.9% of trans feminine individuals and 2.56% of trans masculine individuals were HIV positive, highlighting the need for targeted prevention efforts. The researchers called for increased focus on this population's unique needs.
A large observational cohort study of 134,672 people with HIV found significant disparities in the uptake of dolutegravir, a preferred HIV medication, among women of reproductive age. Only 29% of female patients aged 16-49 years had initiated dolutegravir, compared to 58% of male patients.
The US HIV treatment population is projected to increase by 36% by 2030, with older adults making up nearly a quarter of users. The population is expected to shift towards more older age groups, with nearly one in four people with HIV aged 65 or older by 2030.
A systematic literature review found HIV seroprevalence in five key populations: men who have sex with men (MSM), people who inject drugs (PWID), prisoners, sex workers, and transgender people. The review identified significant gaps in data, particularly for transgender individuals.
A new study published in PLOS Global Public Health has mapped the distance to HIV care services in sub-Saharan Africa, highlighting that 7 million people live more than 10 minutes away and 3 million people live more than 30 minutes away. The research aims to develop cost-effective policies for HIV interventions in underserved areas.
Researchers emphasize the need for monitoring drinking water for HIV medications, as they can contaminate rivers and streams through wastewater. The lack of regulation on pharmaceuticals in wastewater treatment plants poses a significant challenge in ensuring safe drinking water.
Researchers at University of California San Diego School of Medicine identified the anterior insula's role in predicting and emotionally processing pain in HIV-DSP patients. The study suggests that reduced anterior insula activity or increased cingulate activity may improve pain outcomes for these patients.
Researchers found that one person relied on high levels of immune cells to control the virus, while another used strong neutralizing antibodies. This study may lead to the development of new treatments to help people with HIV put the virus into remission without taking lifelong medication.
Researchers found that optimizing energy metabolism through autophagy can improve the immune system response in HIV-affected cells, providing a potential therapeutic approach. This metabolic optimization enables CD4 lymphocytes to better defend against HIV-1 by secreting IL-21, a key protein in defense against the virus.
Researchers used exosomes to deliver a novel anti-HIV protein into infected mouse cells, silencing HIV replication and reducing its presence in the bone marrow, spleen, and brain. The treatment shows promise for future delivery methods for HIV and other brain diseases.
Researchers at Temple University's Lewis Katz School of Medicine have been awarded a prestigious grant from the National Institutes of Health to develop novel treatments for individuals living with HIV using CRISPR technology. The $4.8M grant will fund four major research laboratories working towards eliminating HIV DNA from infected c...
A Kaiser Permanente study found strong adherence to HIV-prevention drug therapy soon after prescription, but inconsistent use among vulnerable groups. The study suggests that targeted strategies are needed to support the effective use of PrEP in high-risk populations.
The APPLI study aims to assess the perceptions and preferences of people living with HIV on long-acting injectable antiretroviral therapies. The study will explore how to support adherence and integrate these therapies into Ryan White HIV care settings, potentially improving health outcomes for those struggling with daily oral medicati...
A randomized trial found that a shorter course of rifapentine-isoniazid therapy resulted in significantly higher treatment completion rates compared to a longer daily course. The findings suggest that this regimens can be more effective for preventing tuberculosis disease in individuals with HIV, particularly in high-transmission areas.
A new strategy to improve viral suppression among people living with HIV in NYC has been awarded a 5-year, $3.3 million grant. The D2S intervention aims to bolster medication adherence by delivering client-level viral suppression status reports and targeted capacity-building.
The National Institutes of Health has awarded $53 million in annual funding to 10 research organizations to accelerate HIV cure research. A new grant focuses on HIV cure research in infants and children, while expanding international collaborations and exploring innovative approaches such as CRISPR gene-editing technology.
A new study found that only 7% of patients who switched from Truvada to Descovy had a documented clinical reason for doing so, highlighting the need for cost-effective PrEP options. The significant price difference between the two medications may be a major barrier to broad and equitable PrEP use in the US.
The AIDS Clinical Trials Group (ACTG) is commemorating its 40th anniversary by convening a virtual annual meeting. The group has played a critical role in HIV research for nearly four decades, conducting landmark studies that have changed the treatment and care of people living with HIV around the world.
A new study by Flinders University researchers found that people living with HIV/AIDS face significant discrimination in their families, communities, and even among healthcare providers. This stigma can lead to concealment of the condition, self-isolation, and poor access to healthcare services.
A new study finds that adding a small molecule can rip away the cloak shielding HIV-infected immune system cells, making them susceptible to patient's own antibodies. Researchers hope this breakthrough may one day eliminate the need for long-term antiretroviral treatments.
Researchers at MUSC Hollings Cancer Center are evaluating the impact of a proactive opt-out approach to smoking cessation interventions on people living with HIV. The study aims to refine delivery and implementation strategies to increase tobacco treatment uptake and reduce smoking-related health complications.
Researchers at Tokyo Medical and Dental University develop novel molecules that mimic CD4 proteins, preventing HIV particles from entering immune cells. These compounds show promise in reducing side effects while increasing effectiveness in stopping viral proliferation.
The HIV epidemic continues to disproportionately affect marginalized groups, particularly in the US South. Experts recommend allocating resources to areas and populations hardest hit by the epidemic to implement targeted interventions and promote HIV prevention and treatment adherence.
A new study published in Lancet HIV found that life-long antiviral treatment can prevent viral transmission from mother to baby, offering a promising contribution to the WHO's work on HIV prevention. The results showed up to 90% of women under study had suppressed viral levels for four years after starting Option B+ care.
A new study published in The Lancet HIV found that integrating opioid use disorder treatment with HIV care in Vietnam can be effective. The study suggests that countries aiming to expand treatment should consider interventions supporting retention on treatment through family networks, peers, and community health workers.
A study of people living with HIV in Ethiopia found that poverty and labor mobility are associated with high viral loads, indicating treatment failure. The researchers highlight the importance of considering socioeconomic conditions in low-income countries to ensure effective HIV treatment.